Positron emission tomography–computed tomography-associated incidental neoplasms of the thyroid gland

With the increasing use of 18F-fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET-CT) scans in oncology, the finding of thyroid incidentalomas, also popularly described as PET-associated incidental neoplasms (PAINs) of the thyroid gland is not unusual. The 18F-FDG PET-CT...

Full description

Saved in:
Bibliographic Details
Main Authors: K Kamakshi, Arvind Krishnamurthy, V Karthik, Preetha Vinodkumar, R Kumar, K Lakshmipathy
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2020-01-01
Series:World Journal of Nuclear Medicine
Subjects:
Online Access:http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_33_19
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With the increasing use of 18F-fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET-CT) scans in oncology, the finding of thyroid incidentalomas, also popularly described as PET-associated incidental neoplasms (PAINs) of the thyroid gland is not unusual. The 18F-FDG PET-CT scans of all patients who underwent imaging for indications other than thyroid malignancy at our tertiary care center between January 1 and December 31, 2017, were retrospectively reviewed for PAINs of the thyroid. A total of 173718F-FDG PET-CT scans were done at our center in the year 2017. 288 thyroid incidentalomas were detected in the said period; the rate of PET-CT-detected thyroid incidentalomas being 16.58%, focal incidentalomas among them being 11.7%. Only 29 out of 204 patients (14.21%) with focal thyroid incidentalomas in our cohort underwent an aspiration cytology and/or ultrasound. The rate of malignancy among the PET detected focal thyroid incidentalomas in the cohort of patients with a proven diagnosis was 10.34%. Our study highlights the challenges in the evaluation and management of PAIN in a tertiary care oncology setting. None of the factors studied including nodule size and standardized uptake value predicted the risk of malignancy. Clinicians specializing in the management of thyroid nodules need to understand the clinical significance of the PAIN, and we hope that our unique experience adds to the limited clinical information available in this regard.
ISSN:1450-1147
1607-3312